{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:54:18Z","timestamp":1790214858916,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1684\/bdc.2011.1443","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:07:50Z","timestamp":1565726870000},"page":"S19-S34","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S","title":["Gestion des effets secondaires des th\u00e9rapies cibl\u00e9es dans le cancer du rein : effets secondaires cardiovasculaires"],"prefix":"10.1016","volume":"98","author":[{"given":"St\u00e9phane","family":"Ederhy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Duclos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Dominique","family":"Doublet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1443_bib0005","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1684\/bdc.2011.1443_bib0010","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1443_bib0015","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1443_bib0020","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and soraf\u00e9nib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"key":"10.1684\/bdc.2011.1443_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11523-009-0111-3","article-title":"QT interval prolongation among patients treated with angiogenesis inhibitors","volume":"4","author":"Ederhy","year":"2009","journal-title":"Target Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0035","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0040","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0761-8425(08)74418-8","article-title":"Thrombo-embolic risks and bevacizumab: data from the literature and recommendations for the use of anticoagulants and antiaggregants [Article in French]","volume":"25","author":"Senellart","year":"2008","journal-title":"Rev Mal Respir"},{"key":"10.1684\/bdc.2011.1443_bib0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of soraf\u00e9nib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1684\/bdc.2011.1443_bib0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2007.08.053","article-title":"High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor","volume":"53","author":"Pouessel","year":"2008","journal-title":"Eur Urol"},{"key":"10.1684\/bdc.2011.1443_bib0055","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2011.1443_bib0060","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1443_bib0065","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0070","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/annonc\/mdn161","article-title":"First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma","volume":"19","author":"Melichar","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0075","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1345\/aph.1L426","article-title":"Intricacies of bevacizumab-induced toxicities and their management","volume":"43","author":"Gressett","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1684\/bdc.2011.1443_bib0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1443_bib0085","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0090","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"Van der Veldt","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1443_bib0100","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with soraf\u00e9nib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0105","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of soraf\u00e9nib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0110","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/jnci\/djn319","article-title":"Soraf\u00e9nib for older patients with renal cell carcinoma: subset analysis from a randomized trial","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2011.1443_bib0115","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1443_bib0120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1443_bib0125","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1443_bib0130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:35:14Z","timestamp":1602491714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0007455115305233"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1443","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}